Vascular endothelial growth factor (VEGF) B belongs to the VEGF family, but in contrast to VEGF-A, VEGF-B does not regulate blood vessel growth. Instead, VEGF-B controls endothelial fatty acid (FA) uptake and was identified as a target for the treatment of type 2 diabetes. The regulatory mechanisms controlling Vegfb expression have remained unidentified. We show that peroxisome proliferator-activated receptor g coactivator 1a (PGC-1a) together with estrogen-related receptor a (ERR-a) regulates expression of Vegfb. Mice overexpressing PGC-1a under the muscle creatine kinase promoter (MPGC-1aTG mice) displayed increased Vegfb expression, and this was accompanied by increased muscular lipid accumulation. Ablation of Vegfb in MPGC-1aTG mice fed a highfat diet (HFD) normalized glucose intolerance, insulin resistance, and dyslipidemia. We suggest that VEGF-B is the missing link between PGC-1a overexpression and the development of the diabetes-like phenotype in HFD-fed MPGC-1aTG mice. The findings identify Vegfb as a novel gene regulated by the PGC-1a/ERR-a signaling pathway. Furthermore, the study highlights the role of PGC-1a as a master metabolic sensor that by regulating the expression levels of Vegfa and Vegfb coordinates blood vessel growth and FA uptake with mitochondrial FA oxidation.
Vascular endothelial growth factor B (VEGF-B) has been shown to control endothelial fatty acid (FA) transcytosis and tissue accumulation of lipids through regulation of the FA transport proteins (FATPs) FATP3 and FATP4 (1) .
Reduction of VEGF-B levels improves the development of type 2 diabetes in diabetic rodent models by decreasing muscular lipid accumulation (2) . However, the regulation of Vegfb expression is not well understood. Vegfb expression is high in mitochondria-dense tissues (3) , and bioinformatic analysis showed that Vegfb is coexpressed with a set of nuclear-encoded mitochondrial genes, the so-called OXPHOS genes (1) . Peroxisome proliferator-activated receptor g coactivator 1a (Ppargc1a/ PGC-1a) is a major regulator of mitochondrial energy metabolism, and in response to extrinsic factors, PGC-1a binds to and coactivates several transcription factors, including estrogen-related receptor a (Esrra/ERR-a), peroxisome proliferator-activated receptor g (PPARg), and nuclear respiratory factor 1 (NRF1) (4) .
A common pathology in type 2 diabetes is dysfunctional and insufficient muscular mitochondria content (5) , and therefore, elevated PGC-1a expression was expected to be beneficial by inducing mitochondrial biogenesis. Of note, mice overexpressing PGC-1a in skeletal muscle (muscle creatine kinase PGC-1a transgenic [MPGC-1aTG] mice) displayed reduced insulin sensitivity upon high-fat diet (HFD) feeding despite increased mitochondrial density and higher respiratory capacity (6, 7) . Given the coexpression of Vegfb with OXPHOS genes and the role of VEGF-B in ectopic lipid accumulation and insulin resistance, we stipulated that Vegfb expression may be regulated by PGC-1a as well. In the current study, we show that PGC-1a and ERR-a control the expression of Vegfb. This previously undescribed regulatory pathway allows PGC-1a to coordinate FA uptake with mitochondrial FA oxidation through regulation of VEGF-B levels.
RESEARCH DESIGN AND METHODS

Animal Handling
MPGC-1aTG mice (6) were crossed with Vegfb-deficient mice (3) to ultimately create MPGC-1aTG//Vegfb 2/2 mice, and only male age-matched mice from the F3 generation were used. For HFD studies, wild-type (WT), MPGC-1aTG, MPGC-1aTG//Vegfb 2/2 , and Vegfb
2/2
mice where fed 60% HFD (Research Diets) for 12 weeks starting from 5 weeks of age. The study was repeated twice. All animals had ad libitum access to food and water and were housed in standard cages in an environment with 12-h light/dark cycles. All mouse work was conducted in accordance to the Swedish Animal Welfare Board at Karolinska Institutet, Stockholm, Sweden.
Cell Culture
Cell lines were maintained in DMEM supplemented with 10% FBS at 37°C in 5% CO 2 . C2C12 was maintained as described (8) . For nutrient deprivation studies, cells were starved in DMEM.
Bioinformatic Analysis
Putative consensus binding sites for ERR-a (ERR1_Q2) within the first kilobase (kb) promoter and first intron of Vegfb were analyzed using Evolutionary Conserved Region (ECR) Browser, Mulan, and multiTF databases (9) (http:// ecrbrowser.dcode.org). The sequences within the ECRs were fed to Mulan and then continued with multiTF analysis with a predefined factor of 0.80.
Cloning and Mutagenesis
The plasmids pCMX-ERR-a, pcDNA3.1/myc-HisA-PGC1a-FLAG, pTK-LUC, and pCMX-b-Gal and corresponding empty vectors were used in the experiments. PCR fragments of the first kb Vegfb promoter and first Vegfb intron were 
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Acadm, acyl-CoA dehydrogenase, medium chain; Acadvl, acyl-CoA dehydrogenase, very long chain; Acox1, acyl-CoA oxidase 1; B2m, b-2-microglobulin; Cers2, ceramide synthase 2; Cs, citrate synthase; Hk2, hexokinase 2; Slc2a1, solute carrier family 2 (facilitated glucose transporter), member 1; Slc2a4, solute carrier family 2 (facilitated glucose transporter), member 4; Sptlc1, serine palmitoyltransferase, long chain base subunit 1. Table 1 .
Oil Red O Staining
Muscles were dissected, sectioned, and stained with Oil Red O (ORO), and the staining was quantified as previously reported (10) .
Glucose Measurements and Metabolic Tests
Body weights and postprandial blood glucose levels were measured by intraperitoneal glucose tolerance tests (IPGTTs) and intraperitoneal insulin tolerance tests (IPITTs) performed in mice as previously described (2) . Pooled data from at least two independent experiments, totaling 10-14 animals per genotype, were included in the analysis. Metabolic analyses of mouse plasma were performed as previously described (2 
Immunohistological Analyses of Muscle Sections
Muscles were flash frozen in liquid nitrogen, cryosectioned into 12-mm sections, and stained using standard putative Esrra binding sites were mutated plus vectors expressing PGC-1a and ERR-a. C-E: Relative muscular mRNA expression of Ppargc1a, Vegfb, and Esrra (C); Vegfa, Tfam, Ndufa5, Ndufb10, and Cycs (D); and Cd36, Fatp1, Fatp3, and Fatp4 (E) in chow-fed WT, MPGC-1aTG, and MPGC-1aTG//Vegfb 2/2 mice (n = 6-7 for each genotype). Data are mean 6 SEM. *P < 0.05, **P < 0.01, ***P < 0.001, MPGC-1aTG or MPGC-1aTG//Vegfb 2/2 compared with WT; ##P < 0.01, ###P < 0.001, MPGC-1aTG//Vegfb 2/2 compared with MPGC-1aTG; † † †P < 0.001, control construct compared with PGC-1a + ERR-a reporter construct or mutated construct. a.u., arbitrary unit; D, mutated bp; Luc, transcription start site of the luciferase reporter gene.
procedures. The primary antibodies were goat anti-FATP3 (Santa Cruz Biotechnology, Santa Cruz, TX), rat anti-CD31 (BD Biosciences, San Jose, CA), rabbit anti-FATP4 (Santa Cruz Biotechnology), and goat anti-CD31 (R&D Systems, Minneapolis, MN). At least 10 frames per animal within each section were photographed with an AxioVision microscope (Carl Zeiss, Oberkochen, Germany) at 340 magnification. For quantification of the stainings, the number of pixels per square micrometer was calculated using the AxioVision quantification program.
Ex Vivo b-Oxidation Assay b-Oxidation activity was measured in isolated skeletal muscle preparations as previously described (1).
Liquid Chromatography-Mass Spectrometry-Based Lipidomic Analysis
Ten milligrams of muscle tissue were analyzed by ultrafast liquid chromatography-mass spectrometry (LC-MS)-based lipidomic analysis by the Swedish Metabolomics Centre at the Swedish University of Agricultural Sciences. The analyses were carried out as previously described (11) .
Statistics
In all figures, data are presented as mean 6 SEM, with n referring to the number of independent data points. P values were calculated with two-tailed Student t test, and P , 0.05 was considered significant. IPGTT. E and F: Relative mRNA expression of Glut1 (gene name Slc2a1) and insulin-sensitive glucose transporter Glut4 (gene name Slc2a4) (E ) and Hk2, Pdk4, and Cs (F ). Data are mean 6 SEM. Scale bar = 100 mm. Inset magnification 36. *P < 0.05, **P < 0.01, ***P < 0.001, MPGC-1aTG or MPGC-1aTG//Vegfb 2/2 compared with WT; #P < 0.05, ##P < 0.01, MPGC-1aTG//Vegfb 2/2 compared with MPGC-1aTG. Acadm, acyl-CoA dehydrogenase, medium chain; Acadvl, acyl-CoA dehydrogenase, very long chain; Acox1, acyl-CoA oxidase 1; a.u., arbitrary unit; Fasn; fatty acid synthase; Hk2, hexokinase 2; ns, not significant; Slc2a1, solute carrier family 2 (facilitated glucose transporter), member 1; Slc2a4, solute carrier family 2 (facilitated glucose transporter), member 4.
RESULTS
PGC-1a and ERR-a Regulate Vegfb Promoter Activity
To investigate whether Vegfb can be induced by starvation, we monitored the expression levels of Ppargc1a and Vegfb in serum-deprived C2C12 myotubes ( Supplementary  Fig. 1 ). Eight hours of nutrient deprivation induced the expression of both Ppargc1a and Vegfb by 2.5-and 1.5-fold, respectively, and the induction was increased to 3.5-and 1.8-fold after 16 h of starvation (Supplementary Fig. 1A) . The induced expression of Ppargc1a and Vegfb upon nutrient deprivation was confirmed in fibroblast (COS-1) and pericyte precursor (10T1/2) cell lines ( Supplementary Fig. 1B and C) .
We characterized the Vegfb promoter by cloning the first kb of the 59-untranslated region and the first exon and intron of the Vegfb gene in front of a luciferase reporter construct. Plasmids encoding PGC-1a and/or the transcription factors ERR-a, NRF1, or PPARg were then cotransfected with the luciferase reporter construct in COS-1 cells (Fig. 1A) . The results show that only coexpression of PGC-1a and ERR-a induced significant transactivation of the reporter construct. To identify putative ERR-a binding sites in the Vegfb promoter, the murine genomic sequence was analyzed by the ECR Browser, Mulan, and multiTF algorithms (9,12). The analyses identified two ERR-a consensus DNA binding sites (13) located in the 59promoter region (2315 to 2310) and in the first intron of the Vegfb gene (+340 to +345) and one putative binding site (2571 to 2566) (Fig. 1B) . To identify the ERR-a binding sites responsible for the transactivation of the Vegfb promoter, new reporter constructs were generated where each ERR-a binding site was mutated by a single bp substitution. No luciferase activity was detected in the absence of PGC-1a and ERR-a, showing that the Vegfb construct per se did not induce luciferase activity (Fig. 1B, upper bar) . Cotransfection of PGC-1a and ERR-a with WT or modified luciferase constructs revealed that mutating the 2571 to 2566 binding site significantly decreased luciferase activity compared with control reporter constructs (Fig. 1B) . Mutations in the two other ERR-a DNA binding sites did not decrease luciferase activity. However, additional cryptic ERR-a binding sites most likely exist between 20.5 and 0 kb in the Vegfb promoter and in the first intron of the Vegfb gene because reporter constructs of both these genomic regions alone also displayed high luciferase activity (Fig. 1B) .
We crossed MPGC-1aTG mice (6) with Vegfb-deficient animals (3) to ultimately create MPGC-1aTG//Vegfb 2/2 mice. qPCR analysis demonstrated a sevenfold increase in muscular expression of Ppargc1a transcripts in MPGC1aTG mice compared with WT controls (Fig. 1C) . Similar analyses showed six-and threefold upregulation of the expression of Vegfb and Esrra, respectively (Fig. 1C) . MPGC-1aTG mice also showed an approximate twofold upregulation of the previously reported PGC-1a target genes Vegfa; transcription factor A, mitochondrial (Tfam); NADH dehydrogenase (ubiquione) 1 a subcomplex 5 (Ndufa5); NADH dehydrogenase (ubiquione) 1 b subcomplex 10 (Ndufb10); and cytochrome C, somatic (Cycs) antibodies. Quantifications are shown on the right (n = 3-6). Data are mean 6 SEM. *P < 0.05, **P < 0.01, ***P < 0.001, MPGC-1aTG or MPGC-1aTG//Vegfb 2/2 compared with WT; ##P < 0.01, ###P < 0.001, MPGC-1aTG//Vegfb 2/2 compared with MPGC-1aTG. In A, scale bar = 100 mm and inset magnification 36, whereas in D, scale bars = 50 mm and 100 mm in top vs. bottom panels. Acadm, acyl-CoA dehydrogenase, medium chain; Acadvl, acyl-CoA dehydrogenase, very long chain; Acox1, acyl-CoA oxidase 1; a.u., arbitrary unit; Cd31, platelet endothelial cell adhesion molecule; Fasn; fatty acid synthase. ( Fig. 1C and D) . Ablation of Vegfb in MPGC-1aTG mice did not affect the expression of any of these genes.
We analyzed muscular expression of FATPs and several other FA handling proteins previously reported to be regulated by PGC-1a (14) . The expression of fatty acid translocase (Cd36), Fatp1, and Fatp4 was upregulated in MPGC-1aTG mice compared with WT mice (Fig. 1E) . Fatp3, the vascular-specific target of VEGF-B signaling, was downregulated in the MPGC-1aTG//Vegfb 2/2 mice compared with the WT and MPGC-1aTG animals (Fig.  1E) . Taken together, PGC-1a and ERR-a regulate Vegfb expression, which requires at least one intact ERR-a binding site located in the promoter region of Vegfb. In vivo, PGC-1a controls Vegfb expression in parallel with the expression of OXPHOS genes and Vegfa. The expression of the OXPHOS genes was not altered by Vegfb deletion, whereas Fatp3 was downregulated only in the MPGC1aTG//Vegfb 2/2 mice.
Muscular Lipid Accumulation Is Reduced in MPGC-1aTG//Vegfb 2/2 Mice
Muscle sections from WT, MPGC-1aTG, MPGC-1aTG// Vegfb 2/2 , and Vegfb 2/2 mice were stained with ORO to visualize accumulation of neutral lipids. Quantifications showed a fivefold increase in lipid accumulation in MPGC-1aTG compared with WT mice (Fig. 2A ). In contrast, MPGC-1aTG//Vegfb 2/2 mice had almost normalized levels of lipid accumulation (Fig. 2A) . The lowest level of lipid accumulation was detected in Vegfb 2/2 mice, in line with previous results (1).
Intracellular lipids can accumulate either through increased FA uptake, decreased b-oxidation, or increased de novo FA synthesis. Therefore, muscular expression of genes encoding critical enzymes in b-oxidation and de novo FA synthesis were measured by qPCR analysis (Fig. 2B) . The transcript levels of regulatory genes in b-oxidation and de novo FA synthesis were upregulated in MPGC-1aTG compared with WT mice (Fig. 2B) , which is in line with previous reports (7) . No further increase in the expression of any of the genes was detected in MPGC-1aTG//Vegfb 2/2 mice (Fig. 2B) , and in line with previous studies, no difference in expression levels of these genes was detected between WT and Vegfb 2/2 mice (1). Vegfb 2/2 mice have a shift in nutrient utilization toward increased use of glucose and decreased use of FAs compared with WT animals (1). However, on chow diet, no differences in postprandial blood glucose levels or glucose tolerance were detected among WT, MPGC1aTG, MPGC-1aTG//Vegfb 2/2 , and Vegfb 2/2 mice ( Fig.  2C and D) . A minor increase in the muscular expression of Glut4 (gene name Slc2a4) but not of Glut1 (gene name Slc2a1) was detected in MPGC-1aTG//Vegfb 2/2 mice compared with MPGC-1aTG mice (Fig. 2E) . PGC-1a/ ERR-a has been reported to regulate glucose utilization by controlling the expression of several intracellular glucose handling enzymes (15,16) ; therefore, we assessed muscular expression of these transcripts in WT, MPGC-1aTG, MPGC-1aTG//Vegfb 2/2 , and Vegfb 2/2 mice (Fig. 2F) . Muscular pyruvate dehydrogenase kinase 4 (Pdk4) expression was downregulated, with ;60% in MPGC-1aTG//Vegfb 2/2 and Vegfb 2/2 mice compared with MPGC-1aTG mice. A minor increase in citrate synthase (Cs) levels (25%) were detected in MPGC-1aTG// Vegfb 2/2 compared with MPGC-1aTG mice. In summary, no major differences in glucose tolerance, blood glucose levels, or expression of glucose transporters were found between WT and MPGC-1aTG, MPGC-1aTG// Vegfb 2/2 , and Vegfb 2/2 mice on chow diet.
VEGF-B Is Regulated by PGC-1a in HFD Mice and Controls Muscular Lipid Accumulation Through FATPs
To characterize the impact of VEGF-B-driven muscular lipid accumulation of the diabetic phenotype in HFD-fed MPGC-1aTG mice, transcriptional profiling of Vegfb and genes involved in lipid uptake and oxidation were analyzed in chow-and HFD-fed animals. Vegfb expression was induced fourfold by HFD feeding in WT mice compared with chow-fed mice and twofold in HFD-fed MPGC1aTG mice compared with chow-fed MPGC-1aTG mice (Fig. 3A) . HFD feeding did not increase Esrra levels in any of the mouse strains compared with the respective genotype fed the chow diet (Fig. 3A) . However, HFD feeding increased muscular expression of genes encoding FA handling proteins in both WT and MPGC-1aTG mice (Fig.  3A) . Deletion of Vegfb in the HFD-fed MPGC-1aTG mice significantly prevented the upregulation of Fatp4 (Fig.  3A) . On the contrary, the expression of mitochondrial genes was reduced upon HFD feeding in WT, as previously reported (2), and also in MPGC-1aTG mice (Fig. 3B) . Deletion of Vegfb in the HFD-fed MPGC-1aTG preserved the expression of several OXPHOS genes compared with MPGC-1aTG mice (Fig. 3B) . Thus, transcriptional analysis suggested that HFD feeding induced an imbalance between lipid uptake and lipid oxidation, and reducing VEGF-B levels may prevent this, leading to metabolic normalization. To analyze whether ablation of Vegfb reduced muscular FA uptake during HFD, muscular tissue sections from the various genotypes were stained with ORO. Muscular lipid accumulation was increased eightfold in HFD-fed MPGC-1aTG mice compared with WT HFD-fed mice but only fourfold in MPGC-1aTG//Vegfb 2/2 mice *P < 0.05, **P < 0.01, ***P < 0.001, MPGC-1aTG or MPGC-1aTG//Vegfb 2/2 compared with WT; #P < 0.05, ##P < 0.01, MPGC-1aTG// Vegfb 2/2 compared with MPGC-1aTG (n = 3-6). a.u., arbitrary unit; Cers2, ceramide synthase 2; Sptlc1, serine palmitoyltransferase, long chain base subunit 1. (Fig. 4A) . Hence, deletion of Vegfb alone in MPGC-1aTG mice lowered muscular lipid accumulation by 80%. In accordance with our previous findings (2), the lowest levels of lipid accumulation was seen in the HFD-fed Vegfb 2/2 mice. The decreased muscular lipid accumulation in HFDfed MPGC-1aTG//Vegfb 2/2 mice was not due to a compensatory increase in b-oxidation or decrease in de novo FA synthesis because transcript levels of the regulatory genes in these pathways were not altered (Fig. 4B) . We also assessed whether genetic ablation of Vegfb in HFDfed MPGC-1aTG mice directly affected the capacity of b-oxidation by incubating isolated skeletal muscle preparations with 14 C-oleic acid and measured formed 14 CO 2 (Fig. 4C) . However, no differences in the levels of released 14 (Fig. 4D ). CD31, a vessel-specific marker protein, was used to identify vascular localization of the FATPs. The expression of both FATP3 and FATP4 was strongly upregulated in HFD-fed MPGC-1aTG mice compared with HFD-fed WT mice. Strikingly, the protein expression of both FATP3 and FATP4 were downregulated by ;70% and 90% in HFD-fed MPGC-1aTG//Vegfb 2/2 and HFD-fed MPGC-1aTG mice, respectively. In summary, HFD feeding induced the expression of Vegfb and FA handling protein transcripts in both WT and MPGC1aTG mice, and muscular lipid deposition was increased accordingly. Of note, muscular lipid accumulation was dramatically reduced in the MPGC-1aTG//Vegfb 2/2 mice, which was caused by lowered FA uptake through decreased expression of FATP3 and FATP4.
Ablation of Vegfb in HFD-Fed Mice Targets Muscular Lipid Accumulation by Reducing Triglycerides, Diacylglycerols, and Ceramides
High intramyocellular lipid content in both humans and experimental animal models have been shown to be associated with insulin resistance (17, 18) . Specifically, both diacylglycerols (DAGs) derived from lipid droplets and ceramides have been shown to affect insulin signaling and/or insulin-mediated muscular glucose uptake (19) . Therefore, we used ultrafast LC-MS-based Glut4 (gene name Slc2a4) (C) and Hk2, Pdk4, and Cs (D). E and F: IPGTT (E) and IPITT (F) and AUC analyses. Data are mean 6 SEM. Statistical analyses between chow-fed and HFD-fed WT are omitted for clarity. *P < 0.05, **P < 0.01, ***P < 0.001, MPGC-1aTG// Vegfb 2/2 or Vegfb 2/2 compared with WT; #P < 0.05, ##P < 0.01, ###P < 0.001, MPGC-1aTG//Vegfb 2/2 or Vegfb 2/2 compared with MPGC-1aTG. a.u., arbitrary unit; Hk2, hexokinase 2; Slc2a1, solute carrier family 2 (facilitated glucose transporter), member 1; Slc2a4, solute carrier family 2 (facilitated glucose transporter), member 4.
lipidomics to quantify the levels of triglycerides (TGs), DAGs, and ceramides in muscle biopsy specimens from chow-fed WT mice and HFD-fed WT, MPGC-1aTG, MPGC-1aTG//Vegfb 2/2 , and Vegfb 2/2 mice (Fig. 5) . Area under the curve (AUC) analysis of all lipid species showed that MPGC-1aTG//Vegfb 2/2 and Vegfb 2/2 mice had ;35% and 60% lower muscular TG content, respectively, compared with MPGC-1aTG mice (Fig. 5A and B) . Similar analysis showed that muscular levels of DAGs and ceramides were reduced by ;35% and 25% in MPGC1aTG//Vegfb 2/2 mice and by ;70% and 35% in Vegfb 2/2 mice compared with MPGC-1aTG mice (Fig. 5C-F) . To analyze whether VEGF-B controls the degradation of TGs to DAGs or de novo DAG synthesis, we measured muscular expression levels of adipose triglyceride lipase (Atgl) and phospholipid phosphatase 1 (Plpp1) (Fig. 5G) . Expression of Atgl was downregulated in both HFD-fed MPGC-1aTG//Vegfb 2/2 and Vegfb 2/2 mice, suggesting that lower amounts of TGs are available for degradation. No differences were found between genotypes in expression of Plpp1 or in the expression of transcripts coding for key enzymes for ceramide formation ( Fig. 5G and H). We analyzed whether deletion of Vegfb could reverse insulin resistance in HFD-fed MPGC-1aTG mice (Fig. 6) . Postprandial blood glucose levels were normalized in HFD-fed MPGC-1aTG//Vegfb 2/2 and Vegfb 2/2 animals (Fig. 6A) . As previously reported, Vegfb 2/2 mice had an increased body weight compared with WT littermates upon HFD feeding (Fig. 6A) (2) . However, no differences in body weights were detected among WT, MPGC-1aTG, and MPGC-1aTG//Vegfb 2/2 mice (Fig. 6A) . HFD-fed WT and MPGC-1aTG mice but not MPGC-1aTG//Vegfb 2/2 mice developed hyperinsulinemia, whereas HFD-fed Vegfb 2/2 mice displayed moderately increased plasma insulin levels (Fig. 6B) . The HOMA-IR index mirrored the plasma insulin levels (Fig. 6B) . qPCR analysis showed that MPGC-1aTG//Vegfb 2/2 mice had higher Glut4 expression (Fig. 6C) , lower Pdk4 expression (Fig. 6D) , and higher Cs expression (Fig. 6D ) compared with MPGC-1aTG mice, suggesting higher glucose utilization (20) . In line with reduced muscular lipid accumulation and increased expression of glucose handling enzymes, the HFD-fed MPGC-1aTG//Vegfb 2/2 and Vegfb 2/2 mice showed improved glucose tolerance and insulin sensitivity compared with HFD-fed WT and MPGC-1aTG mice ( Fig. 6E and F) .
To visualize how insulin resistance correlated to VEGF-B signaling and muscular lipid accumulation, we plotted muscular lipid content and measurements of insulin resistance in individual HFD-fed mice (Fig. 7A) . HFD-fed MPGC-1aTG were characterized by high muscular lipid content and insulin resistance. Reducing Vegfb 2/2 levels in HFD-fed MPGC-1aTG mice strongly affected lipid accumulation and increased insulin sensitivity. In summary, deletion of Vegfb can completely prevent insulin resistance in HFD-fed MPGC-1aTG mice.
In addition to insulin resistance, dyslipidemia is a key feature of type 2 diabetes. Hence, the levels of several plasma lipid species were analyzed in HFD-fed mice ( Fig.  7B and C) . The results showed that HFD feeding leads to increased levels of plasma TGs in WT and MPGC-1aTG mice. In contrast, TG levels were decreased in HFD-fed MPGC-1aTG//Vegfb 2/2 and Vegfb 2/2 mice compared with both WT and MPGC-1aTG animals (Fig. 7B) . LDL and VLDL cholesterol were also decreased in MPGC1aTG//Vegfb 2/2 mice compared with MPGC-1aTG mice, whereas no difference in HDL cholesterol was detected (Fig. 7B) . Similar levels of nonesterified fatty acids (NEFAs) and ketone bodies (KBs) were also detected in MPGC-1aTG and MPGC-1aTG//Vegfb 2/2 mice (Fig. 7C ). In summary, the metabolic tolerance tests showed that genetic deletion of Vegfb in HFD-fed MPGC-1aTG mice is sufficient to prevent hyperglycemia and hyperinsulinemia, reduce insulin resistance, and improve dyslipidemia, thus rescuing the aberrant phenotype of this previously enigmatic mouse model.
DISCUSSION
In this study, we demonstrate that Vegfb is a downstream target of the PGC-1a/ERR-a signaling pathway. PGC-1a is induced by physiological stimuli, including exercise, fasting, and cold temperature (4). Of note, mRNA levels of Vegfb are also increased by nutrient deprivation (Supplementary Fig. 1 ) and during exercise, which is shown in muscles biopsy specimens from mice and human subjects (21, 22) . The coregulation of PGC-1a and VEGF-B ensures that lipid uptake from the circulation is coordinated with tissue lipid oxidation (Fig. 7D) . PGC-1a/ERR-a have also been shown to induce VEGF-A levels and angiogenesis in skeletal muscle in vivo during starvation (8, (23) (24) (25) . Thus, PGC-1a and ERR-a coordinate VEGF-A and VEGF-B expression levels, mitochondrial biogenesis, and lipid oxidation not only by controlling vessel growth but also by regulating lipid uptake.
Given the impact of PGC-1a as the main activator of mitochondrial biogenesis and energy metabolism, efforts have been made to elucidate the role of PGC-1a in metabolic conditions such as insulin resistance and type 2 diabetes. The muscular expression of Ppargc1a and OXPHOS genes is reduced in patients with type 2 diabetes, suggesting that low PGC-1a activity could be the underlying mechanism of type 2 diabetes (26, 27) . Therefore, it was surprising and paradoxical that HFD-fed MPGC1aTG mice developed insulin resistance and type 2 diabetes (7) . In this study, we have unraveled the mechanism underlying the diabetic phenotype reported for the HFD-fed MPGC-1aTG mice (7) . We show that muscular overexpression of PGC-1a upregulates Vegfb levels, driving FA uptake and tissue accumulation and, as a consequence, insulin resistance. Inactivation of Vegfb in HFDfed MPGC-1aTG mice reduced ectopic lipid accumulation and the development of type 2 diabetes by reduced protein levels of endothelial FATPs. Hence, the HFD-induced insulin resistance in MPGC-1aTG mice first described by Choi et al. (7) is most likely caused by a PGC-1a-dependent upregulation of Vegfb expression.
Ablation of Vegfb in MPGC-1aTG mice did not affect plasma levels of NEFAs or KBs, despite reduction of muscular lipid accumulation. The current data agree with that of Choi et al. (7) , which showed that HFD-fed MPGC1aTG mice had lower plasma levels of KB, despite increased muscular FA inflow. We have previously shown that reducing VEGF-B levels in db/db mice reduced both muscular lipid accumulation and plasma levels of NEFAs and KBs (2) . Furthermore, lipid infusions in unchallenged Vegfb 2/2 mice redirected lipids from the peripheral tissues to the adipose tissue (AT) (1) . PGC-1a is described as a regulator of several myokines shown to induce alterations in the AT (22) . Therefore, the lack of differences in plasma NEFA levels between MPGC-1aTG and MPGC1aTG//Vegfb 2/2 could be caused either by the effect of PGC-1a on AT tissue or by VEGF-B-dependent shunting of lipids to the AT.
Efforts have been made to try to link the VEGF-B signaling pathway to insulin resistance in humans, but it was reported that serum VEGF-B levels did not differ between patients with type 2 diabetes and healthy control subjects (28). However, a major confounding factor was that the trial enrolled patients taking oral antidiabetic drugs, such as metformin and thiazolidinediones. The authors showed that thiazolidinediones reduced circulating levels of VEGF-B. Similarly, in a more recent clinical trial of metformin treatment in women with polycystic ovary syndrome and insulin resistance, metformin was shown to reduce plasma VEGF-B levels (29) . This trial enrolled only patients who had not received antidiabetic drugs within the past 3 months before the metformin treatment was initiated. Measurements of serum VEGF-B levels before metformin treatment showed that VEGF-B levels were increased in the subjects with insulin resistance and correlated positively with insulin resistance. In addition, gene association studies have linked the VEGF-B signaling pathway to insulin resistance in humans because a sequence variant in Fatp4 was identified to be associated with the metabolic syndrome and insulin resistance (30) . Moreover, serum VEGF-B levels as well as AT Vegfb expression have been shown to be upregulated in patients who are obese (31, 32) . Taken together, several human studies have shown interesting links among VEGF-B levels, obesity, and insulin resistance.
In summary, the current study identifies Vegfb as a downstream target of the PGC-1a/ERR-a signaling pathway and a mediator of the PGC-1a-induced adverse effects upon HFD feeding. We provide evidence that tissue metabolism is intimately linked to the functional features of the vasculature and highlights the importance of PGC1a as a major metabolic sensor/regulator to coordinate respiratory capacity with vessel growth through VEGF-A and lipid uptake through VEGF-B.
